LEVELS AND CORRELATIONS OF L-ARGININE DEPENDI NG ON THE STAGES OF CARDI ORENAL METABOLI C SYNDROME
DOI:
https://doi.org/10.32689/2663-0672-2025-4-7Keywords:
L-arginine, cardiorenal metabolic syndrome, heart geometry, middle mass molecules, lipid parametersAbstract
The levels of arginine, a conditionally essential aminoacid, the L-form of which (L-ARG) is involved in nitric oxide metabolism, the ornithine cycle, creatinine production, and immune system support, are still not precisely known depending on the cardiorenal metabolic syndrome (CRMS) stages. Objective: to determine the levels and correlations of L-arginine depending on the cardiorenal metabolic syndrome stages. Materials and methods. 108 patients with chronic forms of coronary heart disease (CHD) were investigated. Patients were divided into 6 groups according the stage of CRMS: G0, G1, G2, G3a, G3b, G4. 12 people without cardiovascular and metabolic diseases formed the control group. The level of L-ARG in the blood was determined by reaction with α-naphthol (norm 13-28 μg/ ml), middle mass molecules (MMM) total and at different wave lengths in blood and urine were detected spectrophotometrically. The results were statistically processed. The significance level was taken as p<0.05. Results. The L-ARG level did not depend on the presence of CRMS and its stage. The L-ARG correlation with the blood creatinine level was U-shaped. The correlations of L-ARG with other clinical and laboratory parameters were determined depending on the stage of CRMs. Associations with lipid distress indicators, endogenous intoxication, and heart structure were found. The other correlations of L-ARG were different according CRMS stages. In patients with the early stages of the syndrome (G0-1-2), the increase of L-ARG correlated with an increase of blood creatinine and a decrease of urinary MMM excretion. According kidney function deterioration an increase of L-ARG level was associated with an increase of urinary MMM content, a decrease of total cholesterol and low dencity lipoproteins, and left ventricular dilation. Conclusion. The content of L-arginine did not depend on the CRMS presence and its stage. The correlations of L-arginine were different, associated with the heart geometry, the middle mass molecules content and lipid parameters
References
Au A. Y. M, Mantik K., Bahadory F., Stathakis P., Guiney H., Erlich J., et al. Plasma arginine metabolites in health and chronic kidney diseasе. Nephrol Dial Transplant. 2023. 38(12), 2767–2775. doi: 10.1093/ndt/gfad108
Chen Y., Dai M. T., Gong G. H. L-arginine overdose is a potential risk factor for myocardial injury in patients with type 2 diabetes. World J Diabetes. 2025. 16(5), 104409. doi: 10.4239/wjd.v16.i5.104409
Dimeji I. Y., Abass K. S., Audu N. M., Ayodeji A. S. L-Arginine and immune modulation: A pharmacological perspective on inflammation and autoimmune disorders. Eur J Pharmacol. 2025. 997, 177615. doi: 10.1016/j.ejphar.2025.177615
Fiordelisi A., Cerasuolo F. A., Avvisato R., Buonaiuto A., Maisto M., Bianco A., et al. L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy. Cardiovasc Diabetol. 2024. 23(1), 450. doi: 10.1186/s12933-024-02490-x.
Fung T. S., Ryu K. W., Thompson C. B. Arginine: at the crossroads of nitrogen metabolism. EMBO J. 2025. 44(5), 1275–1293. doi: 10.1038/s44318-025-00379-3
Glavan M. R., Socaciu C., Socaciu A. I., Milas O., Gadalean F., Cretu O. M., et al. Targeted Analysis of Serum and Urinary Metabolites for Early Chronic Kidney Disease. Int J Mol Sci. 2025. 26(7), 2862. doi: 10.3390/ijms26072862
Gu X., Dong Y., Wang X., Ren Z., Li G., Hao Y., et al. Identification of serum biomarkers for chronic kidney disease using serum metabolomics. Ren Fail. 2024. 46(2), 2409346. doi: 10.1080/0886022X.2024.24093
Katanasaka Y., Sunagawa Y., Sakurai R., Tojima M., Naruta R., Hojo Y., et al. Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure. J Biomed Sci. 2025. 32(1), 61. doi: 10.1186/s12929-025-01162-6
Li R., Li Y., Jiang K., Zhang L., Li T., Zhao A., et al. Lighting up arginine metabolism reveals its functional diversity in physiology and pathology. Cell Metab. 2025. 37(1), 291–304.e9. doi: 10.1016/j.cmet.2024.09.011
Mohammadi Z., Ravankhah M., Ahmadi M., Keshavarzian O., Azari I., Abdollahi M., et al. L-arginine impact on inflammatory and cardiac markers in patients undergoing coronary artery bypass graft: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2024. 24(1), 641. doi: 10.1186/s12872-024-04318-8.
Ndumele C. E., Neeland I. J., Tuttle K. R., Chow S. L., Mathew R. O., Khan S. S., et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association Circulation. 2023. 148(20), 1636–1664. doi: 10.1161/CIR. 0000000000001186
Scherpinski L. A., König J., Maas R. Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivative. Int J Mol Sci. 2025. 26(16), 7899. doi: 10.3390/ijms26167899
Thakur M. R., Tupe R. S. l-Arginine: A multifaceted regulator of diabetic cardiomyopathy. Biochem Biophys Res Commun. 2025. 761, 151720. doi: 10.1016/j.bbrc.2025.151720
Winkler M. S., Bahls M., Böger R. H., Ittermann T., Dörr M., Friedrich N., Schwedhelm E. Association of Asymmetric and Symmetric Dimethylarginine with Inflammation in the Population-Based Study of Health in Pomerania. Biomolecules. 2023. 13(11), 1612. doi: 10.3390/biom13111612
Yurdagul A. Jr., Subramanian M., Wang X., Crown S. B., Ilkayeva O. R., Darville L., et al. Macrophage Metabolism of
Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury Cell Metab. 2020. 31(3), 518–533. e10. doi: 10.1016/j.cmet.2020.01.001
